Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20820408 | 1.00 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL17815802 | 1.00 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL30608311 | 0.83 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL26938717 | 0.83 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL17799000 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL3199220 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL3208327 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL13007712 | 0.82 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4761203 | 0.82 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL4714734 | 0.82 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| EP-3019478-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | SLC6A2 792/4885SLC6A4 1157/4885SLC6A3 1729/4885 |
| US-10233191-B2 | Fused piperidine amides as modulators of ion channels | TRPV1, TRPA1, KCNJ2 | SLC6A2 1335/4885SLC6A4 691/4885SLC6A3 1160/4885 |
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | SLC6A2 1335/4885SLC6A4 691/4885SLC6A3 1160/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | SLC6A2 639/4885SLC6A4 876/4885SLC6A3 1305/4885 |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | SLC6A2, HTR3C, SLC6A3 | SLC6A2 1/4885SLC6A4 11/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.